The latest price target for UroGen Pharma (NASDAQ:URGN) was reported by EF Hutton on November 6, 2024. The analyst firm set a price target for $25.00 expecting URGN to rise to within 12 months (a possible 116.45% upside). 23 analyst firms have reported ratings in the last year.

The latest analyst rating for UroGen Pharma (NASDAQ:URGN) was provided by EF Hutton, and UroGen Pharma maintained their buy rating.

There is no last upgrade for UroGen Pharma

The last downgrade for UroGen Pharma Ltd happened on February 8, 2023 when Jefferies changed their price target from $35 to $10 for UroGen Pharma Ltd.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of UroGen Pharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for UroGen Pharma was filed on November 6, 2024 so you should expect the next rating to be made available sometime around November 6, 2025.

While ratings are subjective and will change, the latest UroGen Pharma (URGN) rating was a maintained with a price target of $25.00 to $25.00. The current price UroGen Pharma (URGN) is trading at is $11.55, which is out of the analyst’s predicted range.